Meanwhile, Heitz et al. claimed that selective β-blockers intake did not influence the prognosis for ovarian cancer patients.129 Regarding neurotrophic factors, NGF, BDNF, and their TrK receptors are the current research hotspots. This evidence concerns the gene BDNF and ovarian cancer.